PT2753355T - Vírus herpes simplex oncolítico e suas utilizações terapêuticas - Google Patents
Vírus herpes simplex oncolítico e suas utilizações terapêuticasInfo
- Publication number
- PT2753355T PT2753355T PT12830105T PT12830105T PT2753355T PT 2753355 T PT2753355 T PT 2753355T PT 12830105 T PT12830105 T PT 12830105T PT 12830105 T PT12830105 T PT 12830105T PT 2753355 T PT2753355 T PT 2753355T
- Authority
- PT
- Portugal
- Prior art keywords
- herpes simplex
- simplex virus
- therapeutic uses
- oncolytic herpes
- oncolytic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161532335P | 2011-09-08 | 2011-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2753355T true PT2753355T (pt) | 2019-02-01 |
Family
ID=47832785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT12830105T PT2753355T (pt) | 2011-09-08 | 2012-09-07 | Vírus herpes simplex oncolítico e suas utilizações terapêuticas |
Country Status (14)
Country | Link |
---|---|
US (5) | US9623059B2 (pt) |
EP (1) | EP2753355B1 (pt) |
CA (1) | CA2846372C (pt) |
CY (1) | CY1121591T1 (pt) |
DK (1) | DK2753355T3 (pt) |
ES (1) | ES2704632T3 (pt) |
HR (1) | HRP20182194T1 (pt) |
HU (1) | HUE041799T2 (pt) |
LT (1) | LT2753355T (pt) |
PL (1) | PL2753355T3 (pt) |
PT (1) | PT2753355T (pt) |
RS (1) | RS58146B1 (pt) |
SI (1) | SI2753355T1 (pt) |
WO (1) | WO2013036795A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA39818A (fr) * | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
EP4226936A3 (en) * | 2015-03-05 | 2023-09-27 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
EP3805376A1 (en) * | 2016-01-08 | 2021-04-14 | Replimune Limited | Engineered virus |
MX2019000252A (es) * | 2016-06-30 | 2019-10-09 | Oncorus Inc | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. |
US11298420B2 (en) * | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
US20200009204A1 (en) | 2017-03-15 | 2020-01-09 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
US11306292B2 (en) | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
DK3661954T3 (da) | 2017-08-03 | 2022-04-19 | Amgen Inc | Interleukin-21-muteiner og fremgangsmåder til behandling |
EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
WO2019075233A1 (en) * | 2017-10-12 | 2019-04-18 | Massachusetts Eye And Ear Infirmary | METHODS FOR RAPID DETECTION AND IDENTIFICATION OF PATHOGENIC OLEITY AGENTS |
WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
KR20200110358A (ko) | 2018-01-12 | 2020-09-23 | 암젠 인크 | 항-pd-1 항체 및 치료 방법 |
US11390650B2 (en) | 2018-02-05 | 2022-07-19 | The Brigham And Women's Hospital, Inc. | Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens |
US20210252135A1 (en) * | 2018-06-21 | 2021-08-19 | Replimune Limited | Treatment using oncolytic virus |
TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
MX2021007639A (es) | 2018-12-27 | 2021-08-11 | Amgen Inc | Formulaciones de virus liofilizadas. |
JP2022522817A (ja) | 2019-03-05 | 2022-04-20 | アムジエン・インコーポレーテツド | がんを治療するための腫瘍溶解性ウイルスの使用 |
WO2020181058A1 (en) | 2019-03-05 | 2020-09-10 | Massachusetts Institute Of Technology | Dna launched rna replicon system (drep) and uses thereof |
TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
CN111850126B (zh) * | 2020-08-06 | 2022-11-01 | 北京市神经外科研究所 | 溶瘤病毒在葡萄膜黑色素瘤治疗上的应用、治疗效果的标记物及其检测试剂 |
US20240226207A1 (en) | 2021-05-05 | 2024-07-11 | Janssen Biotech, Inc. | Universal retargeting of oncolytic hsv |
WO2024073416A2 (en) * | 2022-09-26 | 2024-04-04 | The General Hospital Corporation | Modified oncolytic herpes simplex virus (ohsv) and methods of use thereof |
WO2024134495A1 (en) * | 2022-12-20 | 2024-06-27 | Janssen Biotech, Inc. | Oncolytic virus and uses thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4818694A (en) | 1982-07-20 | 1989-04-04 | American Cyanamid Company | Production of herpes simplex viral protein |
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
FR2629818B1 (fr) | 1988-04-06 | 1990-11-16 | Centre Nat Rech Scient | Procede de preparation du taxol |
US5071743A (en) | 1989-10-27 | 1991-12-10 | Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada | Process for conducting site-directed mutagenesis |
FR2662441B1 (fr) | 1990-05-22 | 1992-10-23 | Rhone Poulenc Sante | Procede de preparation enantioselective de derives de la phenylisoserine. |
FR2662440B1 (fr) | 1990-05-22 | 1992-07-31 | Rhone Poulenc Sante | Procede de preparation stereoselective de derives de la phenylisoserine. |
JP3442774B2 (ja) | 1991-07-01 | 2003-09-02 | バーレックス ラボラトリーズ,インコーポレイティド | 新規な突然変異誘発法および組成物 |
FR2678833B1 (fr) | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US5554601A (en) | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
FR2722191B1 (fr) | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle |
US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
US6242222B1 (en) | 1996-06-07 | 2001-06-05 | Massachusetts Institute Of Technology | Programmed sequential mutagenesis |
US5780270A (en) | 1996-07-17 | 1998-07-14 | Promega Corporation | Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity |
US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
JP2003501445A (ja) | 1999-06-08 | 2003-01-14 | ユーエイビー リサーチ ファンデーション | 外来遺伝子を発現するヘルペス単純ウイルスおよびそれによる癌の治療方法 |
IL131212A0 (en) * | 1999-08-03 | 2001-01-28 | Yissum Res Dev Co | Recombinant virus and live-virus vaccines |
US7223593B2 (en) * | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
US6682892B2 (en) | 2000-07-13 | 2004-01-27 | Pharmacia & Upjohn Company | Method for treating herpes viruses |
ATE508635T1 (de) | 2001-03-27 | 2011-05-15 | Catherex Inc | Virusvektoren und ihre verwendung bei therapeutischen methoden |
GB0317511D0 (en) * | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
WO2006002394A2 (en) * | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
US20100092435A1 (en) * | 2006-12-07 | 2010-04-15 | Emmanuel Jacques Henri Joseph Wiertz | Use of a varicellovirus tap-inhibitor for the induction of tumor-or virus-specific immunity against teipp |
-
2012
- 2012-09-07 CA CA2846372A patent/CA2846372C/en active Active
- 2012-09-07 HU HUE12830105A patent/HUE041799T2/hu unknown
- 2012-09-07 WO PCT/US2012/054206 patent/WO2013036795A2/en active Application Filing
- 2012-09-07 LT LTEP12830105.8T patent/LT2753355T/lt unknown
- 2012-09-07 PT PT12830105T patent/PT2753355T/pt unknown
- 2012-09-07 US US14/343,108 patent/US9623059B2/en active Active
- 2012-09-07 DK DK12830105.8T patent/DK2753355T3/en active
- 2012-09-07 SI SI201231454T patent/SI2753355T1/sl unknown
- 2012-09-07 ES ES12830105T patent/ES2704632T3/es active Active
- 2012-09-07 RS RS20181581A patent/RS58146B1/sr unknown
- 2012-09-07 EP EP12830105.8A patent/EP2753355B1/en active Active
- 2012-09-07 PL PL12830105T patent/PL2753355T3/pl unknown
-
2017
- 2017-04-17 US US15/489,514 patent/US10105404B2/en active Active
-
2018
- 2018-09-10 US US16/126,370 patent/US10456432B2/en active Active
- 2018-12-27 HR HRP20182194TT patent/HRP20182194T1/hr unknown
-
2019
- 2019-01-24 CY CY20191100111T patent/CY1121591T1/el unknown
- 2019-09-20 US US16/578,178 patent/US11147846B2/en active Active
-
2021
- 2021-10-15 US US17/502,700 patent/US20220031779A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK2753355T3 (en) | 2019-01-28 |
EP2753355B1 (en) | 2018-10-24 |
CA2846372A1 (en) | 2013-03-14 |
HUE041799T2 (hu) | 2019-05-28 |
EP2753355A2 (en) | 2014-07-16 |
US20200113956A1 (en) | 2020-04-16 |
WO2013036795A3 (en) | 2014-05-15 |
US20220031779A1 (en) | 2022-02-03 |
LT2753355T (lt) | 2019-01-25 |
US10456432B2 (en) | 2019-10-29 |
US20180369301A1 (en) | 2018-12-27 |
RS58146B1 (sr) | 2019-02-28 |
US20150110822A1 (en) | 2015-04-23 |
ES2704632T3 (es) | 2019-03-19 |
US9623059B2 (en) | 2017-04-18 |
HRP20182194T1 (hr) | 2019-02-22 |
PL2753355T3 (pl) | 2019-04-30 |
CY1121591T1 (el) | 2020-07-31 |
EP2753355A4 (en) | 2015-05-06 |
US10105404B2 (en) | 2018-10-23 |
US20170216381A1 (en) | 2017-08-03 |
SI2753355T1 (sl) | 2019-02-28 |
US11147846B2 (en) | 2021-10-19 |
WO2013036795A2 (en) | 2013-03-14 |
CA2846372C (en) | 2021-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20182194T1 (hr) | Onkolitički herpes simpleks virus i njegova terapeutska uporaba | |
IL262123A (en) | Influenza virus vaccines and their uses | |
IL245312B (en) | Recombinant oncolytic herpes simplex virus | |
HK1208349A1 (en) | Biomarkers and combination therapies using oncolytic virus and immunomodulation | |
HK1199211A1 (en) | Influenza virus vaccines and uses thereof | |
HK1187337A1 (zh) | 喹唑啉二酮及其應用 | |
EP2723855A4 (en) | MUTANTS OF THE INFLUENZAVIRUS AND ITS USE | |
EP2726097A4 (en) | HERPES VIRUS VACCINE AND METHOD OF USE | |
HRP20160573T1 (hr) | Herpes simplex virusna cjepiva | |
HK1210475A1 (en) | Herpes simplex virus vaccine | |
EP2802649A4 (en) | PURIFICATION OF HERPES VIRUSES | |
EP2747779A4 (en) | VACCINE AGAINST HERPES SIMPLEX VIRUS IN THE FORM OF NANOEMULSION | |
EP2576581A4 (en) | RECOMBINANT RNA VIRUSES AND USES THEREOF | |
EP2768797A4 (en) | NEW MODIFIED CLASSICS AND ITS USES | |
EP2694542A4 (en) | HERPES SIMPLEX VIRUS | |
EP2616478A4 (en) | ANTI-HEPARAN SULPHATE PEPTIDES BLOCKING HERPES SIMPLEX IN VIVO VIRUS INFECTION | |
EP2920312A4 (en) | ONCOLYTIC HSV1 VECTORS AND METHODS OF USING SAME | |
IL232809A0 (en) | Carboxamides converted at position 2 in isothiazolopyridine and their use as medicinal preparations | |
GB201215184D0 (en) | Therapeutic virus | |
GB201116585D0 (en) | Methods and uses in viral infection |